ESMO Magnitude of Clinical Benefit Scale ESMO/theLancet Oncology Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, July 01, 2015

ESMO Magnitude of Clinical Benefit Scale ESMO/theLancet Oncology



ESMO (website)

 A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)


The ESMO-MCBS will be a dynamic tool and its criteria will be revised on a regular basis.

theLancet Oncology
abstract

 Several new cancer medicines are of little clinical benefit to patients, suggests a new study by investigators from the European Society for Medical Oncology (ESMO). The investigators devised a “validated and reproducible” method to assess the magnitude of cancer medicines' clinical benefits—called the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS).

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.